Atara Biotherapeutics
ATRA
109 hedge funds and large institutions have $131M invested in Atara Biotherapeutics in 2023 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 42 increasing their positions, 38 reducing their positions, and 20 closing their positions.
1,754% more call options, than puts
Call options by funds: $1.82M | Put options by funds: $98K
11% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 38
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.2% less ownership
Funds ownership: 3.69% → 3.49% (-0.2%)
8% less funds holding
Funds holding: 118 → 109 (-9)
10% less capital invested
Capital invested by funds: $146M → $131M (-$15.3M)
45% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$1.69M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.21M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$1.05M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$979K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$958K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$2.29M |
| 2 |
Millennium Management
New York
|
-$2.2M |
| 3 |
BlackRock
New York
|
-$1.01M |
| 4 |
D.E. Shaw & Co
New York
|
-$781K |
| 5 |
Goldman Sachs
New York
|
-$779K |
ATRA Hedge Fund Activity: Q3 2023 in Review
109 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q3 2023, worth a combined $131M — down 10% from $146M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ATRA and 11 opened new positions — a net loss of 9 holders — while 38 trimmed existing stakes and 42 added.
The largest buyer was JP Morgan Chase, adding an estimated $1.69M. The largest seller was Renaissance Technologies, cutting an estimated $2.29M.
- 109 institutional investors held Atara Biotherapeutics (ATRA) as of Q3 2023, down from 118 in Q2 2023.
- Funds reported $131M of Atara Biotherapeutics stock for Q3 2023, down 10% quarter-over-quarter.
- 11 funds opened new Atara Biotherapeutics positions in Q3 2023 and 20 closed out, a net change of -9 holders.
- The largest Atara Biotherapeutics buyer in Q3 2023 was JP Morgan Chase, an estimated $1.69M added.
- The largest Atara Biotherapeutics seller in Q3 2023 was Renaissance Technologies, an estimated $2.29M sold.
Based on aggregated 13F filings for Q3 2023.